Conduent Reports Second Quarter 2026 Results and Advances Transformation Priorities

Conduent reported Q2 2026 revenue of $531M (down 11.9% YoY) and a continuing-ops GAAP pre-tax loss of $(57)M, with adjusted EBITDA of $16M and a 3.0% margin (down 80 bps). The company announced portfolio divestitures of its Transit and Tolling businesses expected to generate about $234M in gross proceeds (plus a 7% equity interest) and said it plans to use most proceeds to reduce debt. Despite the still-weak profitability (adjusted EBITDA down 30.4% YoY), FY2026 outlook calls for $2,150M–$2,250M revenue and adjusted EBITDA of $140M–$170M, while management highlights new AI-enabled products and Medicaid/EBT contract wins.

Analysis

This is more of a balance-sheet repair story than a clean operating inflection. The divestitures reduce complexity and funding risk, but they also shrink the revenue base faster than they fix the underlying margin problem, so equity holders are being asked to underwrite a turnaround with less scale and still-thin profitability. The hidden beneficiary is creditors: every dollar of proceeds used for debt reduction has a larger effect on equity value than another quarter of modest EBITDA improvement, but only if the proceeds are not eaten by transaction costs, retention, or indemnity leakage.

In the next 1-3 months, the key catalyst is not the quarter itself but whether the asset sales close cleanly and translate into a visible leverage step-down. If management can show a meaningful reduction in net debt and a sustained move in adjusted EBITDA margin above the low-single-digit zone, the market can justify a re-rate; if not, this remains a low-growth, low-multiple outsourcing name with execution drag. Over 6-18 months, the rerating case depends on converting government healthcare wins into repeatable, higher-quality revenue rather than one-off implementations.

Contrarian take: the market may be over-focusing on revenue decline and underweighting how much of the reported weakness is deliberate portfolio pruning. But the opposite risk is more important: removing transit/tolling can also remove a cash-generating buffer, making the residual business more sensitive to any slip in government contract renewal or restructuring timing. If the company does not demonstrate at least two quarters of positive free cash flow after transformation charges and a tangible leverage reset, the equity still deserves a distress discount.

Key Decisions for Investors

• CNDT: fade any post-earnings rally over the next 1-3 weeks; the stock likely needs proof of close and debt paydown before it can sustain a higher multiple. Falsifier: confirmed net leverage reduction of >0.5x EBITDA and two consecutive quarters of positive adjusted free cash flow.
• CNDT: if forced to express a view, short on strength rather than into weakness, with a 1-3 month horizon tied to the divestiture-close catalyst. Risk/reward is favorable only if the market overprices the balance-sheet reset before the proceeds are actually de-risked.
• QTRH.TO: small event-driven long only if you want exposure to the acquired tolling asset, but size it modestly because integration risk and financing quality matter more than the headline deal multiple. Falsifier: any sign the acquired business needs more capital than expected or that the retained CNDT equity stake is materially marked down.
• Watchlist: monitor CNDT's next update for net debt, interest expense, and working-capital quality rather than just revenue. If operating cash flow reverts negative after divestiture-related adjustments, the turnaround thesis is weakening.